The hepatitis B virus protein MHBs(t) sensitizes hepatoma cells to TRAIL-induced apoptosis through ERK2
- 14 August 2007
- journal article
- Published by Springer Nature in Apoptosis
- Vol. 12 (10) , 1827-1836
Abstract
The TNF-related apoptosis-inducing ligand (TRAIL) has recently been implicated in the death of hepatocytes under infectious but not normal conditions. Infectious agents, such as hepatitis B virus (HBV), may play important roles in regulating the sensitivity of hepatocytes to TRAIL. Our previous studies showed that HBx, a protein encoded by the HBV genome, enhanced TRAIL-induced apoptosis through upregulating Bax. We report here that another HBV protein called MHBs(t) (C-terminally truncated middle hepatitis B surface protein) is also a potent regulator of TRAIL-induced apoptosis. Overexpressing MHBs(t) in hepatoma cells enhanced TRAIL-induced apoptosis. Mechanistic studies reveal that MHBs(t) had no effect on Bax or TRAIL receptor expression or procaspase-8 activation, but selectively enhanced the activation of ERK2 (extracellular signal-regulated kinase 2) and the degradation of procaspases-3 and 9. ERK2 activation is required for the MHBs(t) effect because ERK2 inhibition by its inhibitor PD98059 significantly reversed TRAIL-induced apoptosis of MHBs(t)-transfected cells. These results establish that unlike HBx, MHBs(t) enhances TRAIL-induced hepatocyte apoptosis through a novel mechanism that involves ERK2. Therefore, manipulating the ERK2 signaling pathway may provide new therapeutic opportunities to contain hepatic cell death during HBV infection.Keywords
This publication has 34 references indexed in Scilit:
- Enhanced TRAIL sensitivity by E1A expression in human cancer and normal cell lines: inhibition by adenovirus E1B19K and E3 proteinsBiochemical and Biophysical Research Communications, 2004
- The Human Papillomavirus Type 16 E5 Protein Impairs TRAIL- and FasL-Mediated Apoptosis in HaCaT Cells by Different MechanismsJournal of Virology, 2002
- Involvement of TRAIL and its receptors in viral hepatitisThe FASEB Journal, 2002
- Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptorsOncogene, 2002
- Inhibition of TRAIL-Induced Apoptosis and Forced Internalization of TRAIL Receptor 1 by Adenovirus ProteinsJournal of Virology, 2001
- MAPK/ERK Overrides the Apoptotic Signaling from Fas, TNF, and TRAIL ReceptorsJournal of Biological Chemistry, 2001
- A new hypothesis of pathogenetic mechanism of viral hepatitis B and CMedical Hypotheses, 2001
- Safety and antitumor activity of recombinant soluble Apo2 ligandJournal of Clinical Investigation, 1999
- TRAIL/Apo-2-ligand-induced apoptosis in human T cellsEuropean Journal of Immunology, 1998
- Opposing Effects of ERK and JNK-p38 MAP Kinases on ApoptosisScience, 1995